drugset / Trial / NCT07685808

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

NCT07685808

Phase 2 Not yet recruiting 360 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Timeline

Start
2026-07-29
Primary completion
2028-01-21
Completion
2028-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Olatorepatide Protein / enzyme biologic

Indications